• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Chief Executive Officer Frank Morgan C.

    4/7/25 4:11:40 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care
    Get the next $SNWV alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    FRANK MORGAN C.

    (Last) (First) (Middle)
    2 CALLE CANDINA, #1701

    (Street)
    SAN JUAN PR 00907

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    SANUWAVE Health, Inc. [ SNWV ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    04/03/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $29.8 04/03/2025 A 1,761 (1) 04/03/2030 Common Stock 1,761 $0 1,761 D
    Explanation of Responses:
    1. Options were fully vested on the grant date.
    /s/ Morgan C. Frank 04/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SNWV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNWV

    DatePrice TargetRatingAnalyst
    9/3/2025$55.00Outperform
    Northland Capital
    7/29/2025$49.00Buy
    Roth Capital
    More analyst ratings

    $SNWV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Opaleye Management Inc. bought $38,361 worth of shares (1,267 units at $30.28) (SEC Form 4)

    4 - SANUWAVE Health, Inc. (0001417663) (Issuer)

    10/9/25 7:09:55 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Large owner Opaleye Management Inc. bought $203,875 worth of shares (7,998 units at $25.49) (SEC Form 4)

    4 - SANUWAVE Health, Inc. (0001417663) (Issuer)

    4/30/25 7:06:51 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    $SNWV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director by Deputization Manchester Management Co Llc sold $4,450,061 worth of shares (144,810 units at $30.73) (SEC Form 4)

    4/A - SANUWAVE Health, Inc. (0001417663) (Issuer)

    12/11/25 3:08:20 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Director by Deputization Manchester Management Co Llc sold $4,450,061 worth of shares (144,810 units at $30.73) (SEC Form 4)

    4 - SANUWAVE Health, Inc. (0001417663) (Issuer)

    12/10/25 9:21:02 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Large owner Opaleye Management Inc. bought $38,361 worth of shares (1,267 units at $30.28) (SEC Form 4)

    4 - SANUWAVE Health, Inc. (0001417663) (Issuer)

    10/9/25 7:09:55 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    $SNWV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Northland Capital initiated coverage on SANUWAVE Health with a new price target

    Northland Capital initiated coverage of SANUWAVE Health with a rating of Outperform and set a new price target of $55.00

    9/3/25 9:10:05 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Roth Capital initiated coverage on SANUWAVE Health with a new price target

    Roth Capital initiated coverage of SANUWAVE Health with a rating of Buy and set a new price target of $49.00

    7/29/25 7:40:14 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    $SNWV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference

    EDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of FDA-approved next-generation wound care products, is pleased to announce that it will be attending the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA from January 12th to January 15th 2026. Those wishing to meet with company management during the conference should reach out to [email protected] to schedule a time. About SanuwaveSanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive directed energy medical systems for the repair and regeneration of skin, muscul

    12/10/25 6:00:00 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply

    Healogics Wound Care Supply adds UltraMIST to its Group Purchasing Organization Healogics iSupply and Sanuwave collaborate to provide UltraMIST as an option for GPO members EDEN PRAIRIE, Minn., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of its UltraMIST product line to Healogics iSupply. With this expansion, UltraMIST becomes an option for iSupply members, including Wound Care Centers®, home health agencies, and skilled nursing facilities. Sanuwave plans to roll out the UltraMIST system to Healogics iSupply members at initi

    12/8/25 6:00:00 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Sanuwave Announces Q3 FY2025 Financial Results

    Q3 2025 revenues were $11.5 million, up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history. Q3 2025 gross margin was 77.9%, versus 75.5% in Q3 2024. GAAP Operating Income was $1.5 million for Q3 2025 versus $2.0 million in Q3 2024. Q3 2025 included stock-based compensation costs of $1.4 million versus $0 in Q3 2024. Company provides guidance for revenues of $13-$14 million for Q4 2025. EDEN PRAIRIE, Minn., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three mo

    11/7/25 6:00:00 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    $SNWV
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by SANUWAVE Health Inc.

    SCHEDULE 13D/A - SANUWAVE Health, Inc. (0001417663) (Subject)

    12/10/25 9:58:51 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    SANUWAVE Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SANUWAVE Health, Inc. (0001417663) (Filer)

    11/7/25 6:10:06 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by SANUWAVE Health Inc.

    10-Q - SANUWAVE Health, Inc. (0001417663) (Filer)

    11/6/25 4:52:01 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    $SNWV
    Leadership Updates

    Live Leadership Updates

    View All

    Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations

    EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the hiring of Dustin Libby as its EVP of commercial operations. Libby brings 20 years of medical device experience focused on commercial growth, sales operations, and launch execution. His career includes leadership roles at Abiomed where, as director of commercial operations, he helped scale a $15M surgical business to over $500M in revenue. Other roles include experience at Smith & Nephew, Arthrex, and Hill-ROM, where he directed sales enablement, operational strat

    6/3/25 7:30:00 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Sanuwave Health Appoints Greg Bazar to Board of Directors

    EDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of Greg Bazar to its Board of Directors. Bazar brings decades of leadership experience in engineering, technology, and cybersecurity to Sanuwave's Board of Directors. He currently serves as Chairman of the Board at Simpatico Systems, a company he founded to deliver advanced IT and cybersecurity solutions. Previously, he was the first employee at intelligent connectivity provider 3D-P, where he played a pivotal role in the company's growth and strategic direction,

    5/28/25 4:05:00 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    $SNWV
    Financials

    Live finance-specific insights

    View All

    Sanuwave Announces Q3 FY2025 Financial Results

    Q3 2025 revenues were $11.5 million, up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history. Q3 2025 gross margin was 77.9%, versus 75.5% in Q3 2024. GAAP Operating Income was $1.5 million for Q3 2025 versus $2.0 million in Q3 2024. Q3 2025 included stock-based compensation costs of $1.4 million versus $0 in Q3 2024. Company provides guidance for revenues of $13-$14 million for Q4 2025. EDEN PRAIRIE, Minn., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three mo

    11/7/25 6:00:00 AM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Sanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial Results

    EDEN PRAIRIE, Minn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, November 7, 2025, at 8:30 AM (ET) to present its Q3 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information  Toll Free: 1-800-274-8461 Toll/International: 1-203-518-9814 Conference ID: SANUWAVE OR click the link for instant telephone access to the event:https://viavid.webcasts.com/starthere.jsp?ei=1741017&tp_key=73ef3b515aMaterials for the conference call will be include

    11/3/25 4:35:00 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care

    Sanuwave Health Announces Preliminary Revenue Results for the Third Quarter 2025 (Ended September 30, 2025)

    Sanuwave announces preliminary revenues of $11.4 million to $11.6 million for the third quarter ended September 30, 2025. This represents the highest quarterly revenues in Company history. Q3 2025 revenue increased between 22% and 24% vs Q3 2024 and between 12% and 14% sequentially vs the prior quarter First nine months of 2025 revenue increased 39-40% vs first nine months of 2024. EDEN PRAIRIE, Minn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the third quarter of 2025 are expected to be in the range of $11.4 to $11.6 millio

    10/6/25 4:01:00 PM ET
    $SNWV
    Medical/Dental Instruments
    Health Care